Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

US Patent 11608383 · Granted Mar 21, 2023

Estimated economic value: $12,640,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treating cancer with a combination of an anti-VEGF antibody and an an2025
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of 2025
Bispecific antibodies against CD3 and CD202025
Bispecific antibodies against CD3 and CD202025
Bispecific antibodies against CD3 and CD202025
Methods of treating cancer with a combination of an anti-PD-1 antibody and an an2025
Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use t2025
Anti-DR5 antibodies and methods of use thereof2025
PD-L1 binding polypeptides for imaging2025
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leuk2024
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leuk2024
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leuk2024